v3.25.0.1
FAIR VALUE MEASUREMENTS (Tables)
 12 Months Ended
Dec. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of Valuation of Financial Instruments Carried at Fair Value by the Applicable Pricing Categories
The table below summarizes the valuation of our financial instruments carried at fair value by the applicable pricing categories (in millions):
Year Ended
December 31, 2024December 31, 2023
Level 1Level 2Level 3Level 1Level 2Level 3
Measured at fair value on a recurring basis:
Assets:
Investment securities$— $— $— $0.1 $— $— 
Foreign currency forward contracts— 5.5 — — 0.6 — 
Cross-currency swaps— 14.2 — — — — 
Interest rate swap agreements— 9.3 — — 30.5 — 
Total assets$— $29.0 $— $0.1 $31.1 $— 
Liabilities:
Foreign currency forward contracts$— $5.6 $— $— $2.7 $— 
Cross-currency swaps— 46.8 — — 172.0 — 
Interest rate swap agreements— 22.6 — — 11.7 — 
Total liabilities$— $75.0 $— $— $186.4 $— 
Measured at fair value on a non-recurring basis:
Assets:
Goodwill(1)
$— $— $— $— $— $118.9 
Contingent consideration(2)
— — 34.5 — — — 
Total assets$— $— $34.5 $— $— $118.9 
(1) During the year ended December 31, 2023, goodwill within our Rare Diseases reporting unit with a carrying value of $208.9 million was written down to a fair value of $118.9 million. The reporting unit was disposed on July 10, 2024 (refer to Note 3).
(2) During the year ended December 31, 2024, contingent consideration was recognized as a result of the divestiture of the Rare Diseases Business (refer to Note 3).
Schedule of Fixed Rate Long-Term Debt
Our fixed rate long-term debt consisted of the following (in millions):
Year Ended
December 31, 2024December 31, 2023
Level 1Level 2Level 1Level 2
Public Bonds
Carrying value (excluding discount)$2,221.8 $— $2,244.4 $— 
Fair value $2,083.9 $— $2,062.2 $—